Bruns Ingmar bought ZNTL
September 30, 2026 · Form 4 insider transaction
Bruns Ingmar bought 9,727 shares of Zentalis Pharmaceuticals, Inc. at $2.18 per share, a transaction worth $21.2K. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
9,727
Price
$2.18
Total value
$21.2K
InsiderBruns Ingmar
Role—
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateSeptember 30, 2026
Filing dateOctober 1, 2026
Shares owned after43,059
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c).; In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026.